In vivo modulation of angiogenesis by beta 2 glycoprotein I

Journal of Autoimmunity

Volumn 35, Issue 3, 2010, Pages 232-240

  Passam, F H ^a,b   Qi, J C ^a,b   Tanaka, K ^a,b   Matthaei, K I ^c,d   Krilis, S A ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c Australian National University   (Australia)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; BETA2 GLYCOPROTEIN 1; HEMOGLOBIN; KI 67 ANTIGEN; MATRIGEL; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MELANOMA; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR GROWTH; WILD TYPE;

ANIMALS; BETA 2-GLYCOPROTEIN I; CELL GROWTH PROCESSES; CELL LINE; COLLAGEN; DRUG COMBINATIONS; FIBROBLAST GROWTH FACTOR 2; HUMANS; INFUSION PUMPS; LAMININ; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; RECOMBINANT PROTEINS; SKIN NEOPLASMS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77957796456     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2010.06.013     Document Type: Article

References (34)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9:653-660.
2. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
3. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
4. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005, 16:159-178.
5. Dass C.R., Tran T.M., Choong P.F. Angiogenesis inhibitors and the need for anti-angiogenic therapeutics. J Dent Res 2007, 86:927-936.
6. Rakic J.M., Maillard C., Jost M., Bajou K., Masson V., Devy L., et al. Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol Life Sci 2003, 60:463-473.
7. Beecken W.D., Engl T., Ringel E.M., Camphausen K., Michaelis M., Jonas D., et al. An endogenous inhibitor of angiogenesis derived from a transitional cell carcinoma: clipped beta2-glycoprotein-I. Ann Surg Oncol 2006, 13:1241-1251.
8. Sakai T., Balasubramanian K., Maiti S., Halder J.B., Schroit A.J. Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis. Am J Pathol 2007, 171:1659-1669.
9. Yu P., Passam F.H., Yu D.M., Denyer G., Krilis S.A. Beta2-glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminal domain. J Thromb Haemost 2008, 6:1215-1223.
10. Nakagawa H., Yasuda S., Matsuura E., Kobayashi K., Ieko M., Kataoka H., et al. Nicked {beta}2-glycoprotein I binds angiostatin 4.5 (plasminogen kringle 1-5) and attenuates its anti-angiogenic property. Blood 2009, 114:2553-2559.
11. Schwarzenbacher R., Zeth K., Diederichs K., Gries A., Kostner G.M., Laggner P., et al. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999, 18:6228-6239.
12. Sheng Y., Sali A., Herzog H., Lahnstein J., Krilis S.A. Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J Immunol 1996, 157:3744-3751.
13. McNeil H.P., Simpson R.J., Chesterman C.N., Krilis S.A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990, 87:4120-4124.
14. Miyakis S., Robertson S., Krilis S. Beta 2 glycoprotein I and its role in the antiphospholipid syndrome-lessons from knockout mice. Clin Immunol 2004, 112:136-143.
15. Yasuda S., Atsumi T., Ieko M., Matsuura E., Kobayashi K., Inagaki J., et al. Nicked beta2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood 2004, 103:3766-3772.
16. Culp W.D., Neal R., Massey R., Egevad L., Pisa P., Garland D. Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. J Proteome Res 2006, 5:1332-1343.
17. Sheng Y., Reddel S.W., Herzog H., Wang Y.X., Brighton T., France M.P., et al. Impaired thrombin generation in beta 2-glycoprotein I null mice. J Biol Chem 2001, 276:13817-13821.
18. Passaniti A., Taylor R.M., Pili R., Guo Y., Long P.V., Haney J.A., et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992, 67:519-528.
19. Min J.K., Han K.Y., Kim E.C., Kim Y.M., Lee S.W., Kim O.H., et al. Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res 2004, 64:644-651.
20. Hansen S., Grabau D.A., Rose C., Bak M., Sørensen F.B. Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density. Lab Invest 1998, 78:1563-1573.
21. Zhang Z., Ramirez N.E., Yankeelov T.E., Li Z., Ford L.E., Qi Y., et al. Alpha2beta1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner. Blood 2008, 111:1980-1988.
22. Widera D., Mikenberg I., Elvers M., Kaltschmidt C., Kaltschmidt B. Tumor necrosis factor alpha triggers proliferation of adult neural stem cells via IKK/NF-kappaB signaling. BMC Neurosci 2006, 7:64.
23. McMahon G.A., Petitclerc E., Stefansson S., Smith E., Wong M.K., Westrick R.J., et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2001, 276:33964-33968.
24. Kleinman H.K. Preparation of basement membrane components from EHS tumors. Curr Protoc Cell Biol 2001, [Chapter 10:Unit 10.2].
25. Guerin J., Sheng Y., Reddel S., Iverson G.M., Chapman M.G., Krilis S.A. Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome. J Biol Chem 2002, 277:2644-2649.
26. Kroon M.E., Koolwijk P., Vermeer M.A., van der Vecht B., van Hinsbergh V.W. Vascular endothelial growth factor enhances the expression of urokinase receptor in human endothelial cells via protein kinase C activation. Thromb Haemost 2001, 85:296-302.
27. Nasarre P., Thomas M., Kruse K., Helfrich I., Wolter V., Deppermann C., et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 2009, 69:1324-1333.
28. Lin K.Y., Wang H.H., Lai S.T., Pan J.P., Chiang A.N. beta(2)-glycoprotein I protects J774A.1 macrophages and human coronary artery smooth muscle cells against apoptosis. J Cell Biochem 2005, 94:485-496.
29. Maiti S.N., Balasubramanian K., Ramoth J.A., Schroit A.J. Beta-2-glycoprotein 1-dependent macrophage uptake of apoptotic cells. Binding to lipoprotein receptor-related protein receptor family members. J Biol Chem 2008, 283:3761-3766.
30. Bu C., Gao L., Xie W., Zhang J., He Y., Cai G., et al. B2-Glycoprotein I is a cofactor of tissue plasminogen activator-mediated plasminogen activation. Arthrit Rheum 2009, 60:559-568.
31. Ansari A.A., Gershwin M.E. Navigating the passage between Charybdis and Scylla: recognizing the achievements of Noel Rose. J Autoimmun 2009, 33:165-169.
32. Whittingham S., Rowley M.J., Gershwin M.E. A tribute to an outstanding immunologist - Ian Reay Mackay. J Autoimmun 2008, 31:197-200.
33. Gershwin M.E. Bone marrow transplantation, refractory autoimmunity and the contributions of Susumu Ikehara. J Autoimmun 2008, 30:105-107.
34. Gershwin M.E. The mosaic of autoimmunity. Autoimmun Rev 2008, 7:161-163.